Tariquidar (formerly XR9576; D06008; XR-9576; D-06008) is a potent and selective noncompetitive inhibitor of P-glycoprotein (P-gp) with potential antineoplastic activity.
Elacridar (formerly GW-120918; GF-120918; GG-918; GW-0918; GF120918; GF120918; GW0918; GG918) is a 3rd generationl and potent P-glycoprotein (P-gp or MDR-1) and BCRP inhibitor that has the potential to overcome P-gp-mediated multidrug resistance (MDR) of the cytotoxic drugs such as doxorubicin.
Tariquidar methanesulfonate hydrate (formerly also known as XR9576) is a novel potent and selective noncompetitive inhibitor of P-glycoprotein (P-gp) with Kd of 5.1 nM in CHrB30 cell line, it reverses drug resistance in MDR cell Lines.
Elacridar HCl (formerly also known as GF120918; GF-120918; GW0918; GG918; GW120918) is a novel and potent P-glycoprotein (P-gp or MDR-1) and BCRP inhibitor.
Encequidar mesylate (HM30181; HM-30181A; Oraxol), the mesylate salt of encequidar, is a novel, highly specific, and orally bioavailable inhibitor of P-glycoprotein (P-gp), which is an adenosine triphosphate (ATP)-binding cassette (ABC) transporter.
NSC23925 2HCl (NSC23925 dihyrochloride) is a novel, potent, selective and effective P-glycoprotein (Pgp) inhibitor that is able to reverse multidrug resistance (MDR), e.g.
Encequidar (formerly HM-30181; HM30181; HM30181A) is a novel, potent, selective, and orally bioavailable inhibitor of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter P-gp (P-glycoprotein).
Valspodar (PSC833; SDZ-PSC 833; PSC-833), a cyclosporin-A analog, is a potent and selective inhibitor/modulator of P-glycoprotein (P-gp or MDR-1, an efflux transporter) being investigated as a potential anti-cancer drug and chemosensitizer.
Zosuquidar 3HCl (formerly D-06387; D06387; RS33295198; LY335979; LY-335979; RS-33295198), the trihydrochloride salt of zosuquidar, is a novel and potent inhibitor P-glycoprotein (P-gp) and modulator of P-gp-mediated multi-drug resistance with potential antitumor activity.
SC144 is a first-in-class small-molecule inhibitor of gp130 with oral activity in ovarian cancer.